semaglutide sales Market Size, Share, Growth & Trends Report, 2033 GLP-1 Market Shift: Semaglutide, Tirzepatide
Description
Diarrhea on GLP-1 is one of the most common gastrointestinal side effects, alongside nausea and constipation
Published on 3/30/2023
The promising results from the Phase III SOUL trial, which demonstrated a 14% reduction in MACE occurrence with Rybelsus, have further validated its role in cardiovascular disease prevention
[Google Scholar] 50.Delgado-Aros S, Vella A, Camilleri M, et al
Based on your consultation, your provider will help you understand which option is best for you
[DOI] [PMC free article] [PubMed] [Google Scholar] 15.Fandio J., Toba L., Gonzlez-Matas L.C., Diz-Chaves Y., Mallo F
